Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Quite the 'crew' now working toward the future of micro dose DMT as a treatment and therapy for stroke patients.
The Company also announces it has appointed Dr. Anthony Rudd and Dr. Robert Simister, both from the U.K., as medical consultants to the Company’s DMT stroke clinical research program. Both Dr. Rudd and Dr. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research. Their primary responsibility will be to help guide the Company’s Phase 2 acute stroke and post stroke therapy clinical trials planned to begin in the U.K. in the latter part of 2022, after the Phase 1 trial has been completed.
Dr. Anthony Rudd
Anthony Rudd, MB, BChir, FRCP, CBE is an emeritus professor of Stroke Medicine at Kings College London and recently retired as a consultant stroke physician at Guy’s and St Thomas’ Hospital. He was the London Stroke Clinical Director from 2010-2019 and the National Clinical Director for Stroke for NHS England from 2013-2019, where he oversaw dramatic improvements in the paradigm of NHS stroke treatment.
For over 20 years he chaired the Intercollegiate Stroke Working Party at the Royal College of Physicians which was responsible for developing the National Clinical Guidelines for Stroke and running the National Sentinel Stroke Audit program. He chaired the National Institute for Health and Care Excellence (NICE) Guidelines Group for Acute stroke and TIA and the NICE Stroke Quality Standards Development Group. He is also past president of the British Association of Stroke Physicians and is Honorary Vice President of the Stroke Association.
Dr. Rudd was educated at Cambridge and King’s College London, receiving his medical degree in 1978. His research interests are stroke rehabilitation, organization of care and quality improvement. He has published over 300 peer reviewed publications and supervised fourteen higher degrees.
He was made a CBE (Commander of the British Empire) in 2013 in recognition of his services to stroke medicine.
Dr. Robert Simister
Robert Simister MA MB BS PhD FRCP is a consultant neurologist and stroke physician as well as an honorary senior lecturer at University College London, where he also serves as the Clinical Lead for the Comprehensive Stroke Service and the Clinical Director of Stroke Medicine and Acute Neurology. Since 2019, he has been the Joint Clinical Director for the London Stroke Clinical Network.
Dr. Simister received his medical degree from the Charing Cross and Westminster Medical School, now part of Imperial College London, and was awarded his PhD in Neuroscience from University College London in 2012. In addition to his consulting and directorial responsibilities, he maintains an active research program directed towards improving outcomes for stroke patients.
“Completing production of a cGMP supply of DMT is a major milestone for the Company’s clinical stroke research program and it ensures that we will have a supply of the drug for our planned Phase 1 and 2 clinical trials,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals Inc. “We are also very pleased to have Dr. Rudd and Dr. Simister join as medical consultants as we now begin the process of planning our Phase 2 studies for both acute stroke and for therapy post stroke.”
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
The forum selected was great for Dr Strassman and Dr Nutt, accepted senior experts in Psyc research.
Important opinions of supporting AGN and the microdose DMT concept for neuron regrowth after Stroke.
Even the excellent Safety history was discussed.
Not enough time for questions of course in today's forum. Especially specifics of AGN's exact moves. Maybe soon.
AGN has the highest level of qualified support in this excellent presentation, IMO...GLTA...
The forum selected was great for Dr Strassman and Dr Nutt, accepted senior experts in Psyc research.
Important opinions of supporting AGN and the microdose DMT concept for neuron regrowth after Stroke.
Even the excellent Safety history was discussed.
Not enough time for questions of course in today's forum. Especially specifics of AGN's exact moves. Maybe soon.
AGN has the highest level of qualified support in this excellent presentation, IMO...GLTA...
Dr Strassman and Dr Nutt talk Stroke...GLTA...
FDA finally throwing out the trash. Maybe making room for something better...GLTA...
https://www.msn.com/en-us/news/us/monoclonal-antibodies-were-doing-nothing-against-omicron-that-s-why-fda-pulled-its-authorization/ar-AATc25x?ocid=msedgntp
My questions were ;
AGN has chosen the doctors to run the clinical trials through Hammersmith. Is there strong enthusiasm from all involved, including the Stroke rehab centers, for this new treatment of micro-dose DMT?
and
With the recent correlation of an increase in Stroke patients due to COVID, will these patients be targeted for treatments?
We all hope this will be much more efficient and much faster than the prolonged IPF/CC done in Australia.
Great line up for this new video. They are Asking for questions. (based on reality and what can actually be answered).
https://www.streetwisereports.com/events/register/?event_id=100&utm_source=SWR_MC
yes, the COVID phase 2 Ifenprodil CT was a 'study' encouraged by the modified standards that we still see for this disease.
We all bought tickets.
As seen in recently posted blogs the data was not bad but the decision needed to be made during the lull before Delta and omicron. BP also was entering the area after their vaccine success. So...?...
The data collected is still viable and pertinent to their application for Ifenprodil SCLC and pancreatic Clinical Trials, IMO. Safety issues were nil.
I expect/hope for AGN to announce progress with the US FDA about these soon, IMO.
BTH/NASH>AGN. The CSO-(NASH) et al determined to moved Ifenprodil forward first with the IPF/CC combo. Yost-UF stuff excited me due to FAIMS. More than half my investment here is BLO $ from the Pot boom days.
Buy, Hold or sell are our options. $30? +-?
...GLTA...
The Uk is suffering with the COVID issue and apparently has an increase in Stroke patients directly related to COVID. There may be considerable support for this treatment from the more realistic and open EU community, I hear.
(lucy in the skys with diamonds)...LOL...
Interesting wording in the PR could have used better definitions. My thoughts in ("")...GLTA...
ie.
"The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, ("6 hr microdose") for durations which have never been clinically studied. (" in humans!")... The resulting data generated will help the Company to plan both its Phase 2 ""acute stroke"!" and ""rehabilitation"!" studies more effectively.
“We look forward to getting our DMT clinical stroke program started with our Phase 1 study at Hammersmith Medicines Research in the UK,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This study will provide """"important information on dosage and duration of our new DMT IV formula""!"" to help us better plan for our Phase 2 study where we plan to test the drug with both ""!""acute and recovering stroke patients""!"".”
Phase 1 DMT Stroke Study Summary
The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion ("6 hr micro-dose ?"). The first part of the study will use a single-escalating dose design aimed at identifying the maximum sub-psychedelic dose, ("in humans?") while the second part will test the effects of repeated administrations ("6 hr micro-dose") of this dose ("in humans""!").
With the support of Hammersmith in theUK and Stroke now strongly related to after effects of COVID this may go pretty fast.
"For Type B and C trials, the notification scheme is not applicable and each application will be fully assessed by the MHRA. They will provide an initial response within 30 days of receipt of a valid application, with an average of 14 days for Phase 1 volunteer studies."
With China conflict possible over Taiwan, there may be trade interruptions.?.
EVs continue to be the future path for vehicles. Hydrogen Power is still farther off and more suited to large projects, IMO...
Will there be a consolidation of Graphite resources by the larger players?
...GLTA...
Seems implied that the Phase 1 trials should be run and the ball rolling well when they go NASDAQ. $100M+ MC? A well-handled set of PRs showing the progress is needed over the next couple months.
Stroke recovery and Cancer tumor treatments are excellent choices for AGN, IMO.
CC can wait until data from the Ausi IPF/CC Phase 2 CT is presented, when these paths are proven or not. IMO.
Math of $2+M in the books implies patience for long time shareholders and restraint from unneeded dilution by the company, IMO. The current pps is well below most folks' average and attractive compared to others.
The converted management shares are now the same as ours and capitol raises are not needed yet, IMO. Tax loss sellers also may return soon. JMHOs. All Good...GLTA...
The dire need for Stroke therapies, now with a related cause being COVID, seems to suggest that the current COVID issues may actually provide patients for the UK - DMT microdose CTs. Maybe we can even look for expedited completion.
" In the EU, stroke is the leading cause of adult disability according to a 2020 study, and Covid has worsened the scenario. The number of patients with stroke requiring long term assistance and rehabilitation has dramatically increased since the outbreak of Covid-19, as well as flu-related strokes in young people. While some stroke survivors will recover, impairment of the upper limbs can become chronic and seriously affect the behaviour of the patient in up to 75% of stroke patients."
from another MB...GLTA...
Pure puke JJ ruined Aviptadil Trials as a treatment for COVID through greed and incompetence then lost Billion$ for investors. IMHFO...
All the 'psyc' companies mentioned are targeting addiction/ptsd/mental health.
AGN seems to be an example of a different medical related use of psychodelia, microdose DMT.
Treating Stroke patients is a very strong and new approach, IMO. Licensing the IP and now with Trials in the UK made a real good hand. IMO.
CC/IPF and Treating SCLC tumors.
So much still on the shelf at AGN from the NASH deal, too...GLTA...
The 'reserved for issuance' of 54M must be wrong.
I just pointed out the possible difference a financing would be between $3 and $20+.
Without sponsors or paying partnerships AGN will eventually need money to run the Phase 2 Trials. (assumed 540k @ $20+)
It's time for hard work from the CEO / CSO / BoD members, etc., to bring the company value up Before raising money.
I agree there is NO reason to do it now. $2.4M on their books?
All Shareholders are already in full Ben Dover.
...GLTA...
540k X $3 to $20 = $?
I would hope to see the Phase 1s (+) for SCLC and Stroke in process and a PPS over $20 before looking for a Private Placement.
Terrible handling of the PRs over the last months, we should be at $10 easily with keen interest in the company's progress. Inept sequences of the PRs Killed that sadly with a severe shareholder's ass kicking.
We need strong progress in the UK with the microdose of DMT trials for Stroke, ASAP... AND a partner/sponsor like the ACS for cancer tumors, ASAP. Could happen...GLTA...
Binge griping on a MB may be a technique that works for some folks investment strategy, GLWT. I obviously dont agree with it.
See my past posts.
The cards NOW on this table are what is needed to be considered if investing in AGNP*, or not, IMO.
SCLC/Pancreatic tumors, CC/IPF follow up with Ifenprodil and
Micro-dosed DMT with CMT for Stroke. Licensed from Dartmouth with CTs in the UK.
Dr W. North, Dr Strassman, Dr Nutt, Dr M. Williams are an impressive list of Scientific advisors supporting and helping design the next CTs...
The $2+M cash on the books may be enough to do a couple Phase 1 Trials +.
Seems like a REAL GOOD hand to me...GLTA....
Everyone voluntarily invested in this company and it's goals.
As stated, some have RE-invested as new cards are seen. It's AGNPD, by the way... DUH...
Any money made or lost on ANY investment I make OR at ANY table is MY responsibility...DUH... Everyone wants to win.
Companies usually TRY to achieve their goals. It pays them much better. It's called incentive. Sometimes there are actual positive or negative circumstances with a speculative investment. SOME investors react or Not.
Good company management reacts to reality and attempts to succeed. Shareholders make the decision to Buy/Hold/Sell based on evaluating the goals, current issues and successes, personnel and the company's future, IMO.
SCLC/Pancreatic tumors, CC/IPF as follow up with Ifenprodil and Micro-dosed DMT with CMT for Stroke in the UK.
Dr W North, Dr Strassman, Dr Nutt, Dr M Williams...
$2+ M cash on the books may be enough to do Phase 1 Trials.
Seems like a REAL and GOOD hand to me...GLTA...
Facts Other People Usually Normally Know, enjoy the wine...
Never been to Canada but played their Pot legalization well and now minerals too, etc, **.
Corporal US Army, drafted.
I take responsibility for my investment decisions and post SOMETIMES here. My ID has changed here for a reason but I am not expanding my bully pulpit.
I dont attempt to dominate. I am not always right in foresight. Better apparently than some. Hindsight.?. Blame the deck of cards or dealer if it makes people feel better. That does Not change the outcome.
Strange there is so much posted hate and still some are here.
This is a SPECULATIVE INVESTMENT where folks take Risks for larger Rewards. DUH.
Some folks sell and buy to avoid Tragic portfolios, increase holdings, etc.
Facts Obfuscating People Usually Never Know.
**New and developing cards, SCLC/pancreatic tumors, CC and IPF, microdose DMT for Stroke.
The covid game for AGN has ended.!. Everyone here took the bite voluntarily. Vaccines won. Next Hand is in play.
...GLTA...
I think he has done as well as possible. The new cards look good to me too...GLTA...
TAKE SOME RESPONSIBILITY FOR YOUR OWN ACTIONS.
Yes, just < 10k, post split. No beer buddies.
...GLTA...
I wish absurd commentors would follow their own 'implied' advice. If someone is worried about jokers and wont accept the R/R involved then **** ***.
BTW, scrapping the company takes it to '$0'. Duh.
Relevant comparisons to other companies in similar businesses have been posted. Successes in Phase 1/2 for ANY of the cards NOW on the table could result in a $100M+ MC, IMO. Multiple successes at Phase 1/2 could result in mid 9 figures, IMO. A fair R/R, IMO...
...GLTA...
The cards are worth 100 X pre R split. Same account value$.
What matters is cash on the books, $2M+ going into the micro dose DMT stroke Phase 1 trial and CC or SCLC Phase 1 tumor trials.
Raising money for Phase 2 Trials next spring is my hope AFTER successes when the paid for Phase 1 trials are approved and completed.
ACS sponsorship for SCLC and/or Pancreatic cancer trials would be nice and is possible, IMO.
. . . GLTA. . .
Other shareholders may want to read this stockhouse post before accepting opinions as facts...JMHFO...
AGN didn't win with COVID.
BUT
New cards are being played. Nasdaq.?.
Ante up or move to another table.?.
Dr North and Ifenprodil SCLC / Pancreatic tumors. CT ASAP.
Dr Strassman and Dr Nutt with lengthy micro dose DMT research. Dartmoth Stroke IP licensed. UK CT in ASAP.
CC Phase 2 Clinical Trial and IPF/CC Study completion ASAP.
...GLTA...
Wine and cheese at the buffet.
Low volume also means most are holding. We have hope in one hand.
Saving those PRs about SCLC and Pancreatic tumors would have been better than another Australia 'almost there'.
Lots of Other actual Big news should be seen soon.
Dr North Represents us for Ifenprodil cancer research.
Dr Strassman AND Dr Nutt are working the DMT - UK micro-dose stuff.
WORLD CLASS...GLTA...
Bad PR sequencing on all this. That does not change the long time value of the drugs and initiatives at AGN. Nasdaq asap with lots of follow ups still to come...GLTA...
A company might need to raise money and reward shareholders with a FS of 2+/1. These strong forward looking successes could move the PPS fast.
Yes, there is fast attrition with many cancers. Even a suggestion of help will fill Clinical Trials for SCLC. Pancreatic. Big Pharma MUST include themselves in any $UCCE$$ related to Cancer. Novartis.
...GLTA...
Thrilled about the up-list process. Your essays have strong points.
Confident of the company progress with DMT Strok micro-dose research in the UK and the Ifenprodil IPF, CC progress.
Ifenprodil SCLC and Pancreatic cancer may attract the BIG support we all are looking for. Not mentioned in the recent video so I hope there are surprises still to come with Cancer.
Just stymied by the timing of the PRs...GLTA...
Yep, releasing the R/S news right after a strong bio-pub, and then holding the UK STROKE updates until the Friday before a Holiday week, THEN releasing BLOCKBUSTER news about SCLC During a Holiday week. Hard to make that stuff up.
HOPE the Quality and Strength of the News will overcome the inept timing of these HUGE Press releases...GLTA...
https://finance.yahoo.com/quote/AGN.CN?p=AGN.CN
My U.S. IRA at * is still at AGNPF, cant buy, PPS @ 6.00 cad.
...GLTA...
AGN.cn
SCLC Phase 1 / IND WITH Pancreatic IND applications.
...GLTA...
Acute Stroke Trials in the UK to start by Jan 2022. Dr Strassman 90's DMT data may help expedite Phase 1 Safety for micro doses.
I am most interested in the Cancer tumor application for Ifenprodil with pre clinical work done at Dartmoth by Dr Smith, another AGN SME.
What is the valuation of just those two, both with strong pre clinical work now.?.
Stand alone CC and finally finishing the on-going IPF/CC study on deck.
IBD and CKD in the company's future arsenal...GLTA...
I have Never seen where a nice Pump video (biopub) is followed by news of a R/S on a midweek PR completely dampening a runup and then releasing FASTASTIC news on a Friday before Holidays.
Could have hit $.10, IMHFO.
ALMOST NO ONE has yet seen or was looking for a Blurb PR/video on mid-day Friday, especially with this significant news. FKN WASTED reactive pump to disaster. FU-CM.
CM pissed in the common soup bowl and 5M shares walked out along with an almost -40% of the MC. I bought from the sellers due to the Ifenprodil and DMT possibilities. I guess there were others with cash ready after the bio-pub but NO ONE expected the R/S PR. Thanks for the 4 week window explanation, BUT.
At least there NOW is a story beginning to go with the R/S-NASDAQ up-list news. Pathetic PR management KILLED the possible enthusiasm from the UK news. SAD.
It takes one hundred 'atta-boys' to become a leader but just one aw-shit cancels them all.
Starting over at the ATL of <$.04.
I give a FUBAR for the handling of this weeks' events.
YES, the Phase 1 - 2a CT plans with microdosed DMT for Acute Strokes should have been announced on Wednesday after the bio-pub video and AGN stock would have been $.10+ possibly.
OR!!!
They COULD HAVE FKN WAITED KNOWING that this 'GREAT' news from the UK was due.
THEN drop the consolidation for the Nasdaq today. DUH. But NO , we get this MH video now.
Handled like a big FUBAR, IMO too.
Driven to <$.04 where as this could be headed for a dime +. +.
Hopefully this news is good enough to OVERCOME this, another FUBAR.
https://themarketherald.ca/algernon-announces-positive-feedback-on-its-planned-phase-1-2a-dmt-human-stroke-study-2021-11-19/
$.06 to .04 / $.05 to .03 = %40
Releasing this kind of critical POSITIVE PR should not been at the start of a Vacation week. The R/S PR should have waited as THAT is confusing. JMHFO.
At least there is NOW a STORY for AGN's future actions/moves.
Time again for long Longs to do some pushing/buying this to $.10+. Maybe $.2s. THAT will change the Whole picture.
Flyer noticed...GLTA...
As*holes couldnt wait a day for the R/S PR. Had to put that out BEFORE something POSITIVE.
FKN -40%.
Now we have to climb back....................!!!!!!!!!!!!!!!!!!!!!!!!
Maybe put some info and PUMP and a KISS BEFORE FKN R/S kazooz.
Yea, I bought some yesterday but AS*hole way to treat your COMMON Investors Mr CM...................................!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.
...GLTA...
https://finance.yahoo.com/news/algernon-announces-positive-feedback-planned-120000416.html
They better have some great news for a $25 IPO. The current value of<$7M is way low comparing what may be possible "IF".
I really thought there would SOMETHING POSITIVE announced this AM to cushion the blow or even provide a boost.
No Halt, no positive PR and apparently no respect.
Possible coulda / maybe stuff like we expected to see BEFORE this R/S stuff;
IPF/CC enrollment or interim evaluation of some positive data,
UK DMT progress,
conditional sponsor,
a partnership,
Ifenprodil Cancer/tumor FDA IND trial approval,
Ifenprodil CC FDA IND trial approval,...
As a resident pumper here and several times fkt even I am pissed.
CM said the 'crew' had done some travel besides the UK trip.(vacation). BulkShyt.
Going to the Nasdaq with no SPLASH/PUMP is beyond stupid. Only a string of positive PRs will save us.
Right now it Sucks to be us buttercups.
There will be few buyers and smaller traders may act like this OTC speculative stock should be a mdna. Painful.
Not even a prospectus.?.
They are semi forcing Longs to support or accept this Ben Dover plan.
ONLY REAL NEWS will help.
fuckashitpiss.
$6.8M @ $.04 market cap ? An additional 200k shares @ IPO of $25 would be a blessing. They better get the PUMP running in the deep end ASAP!!!.
...GLTA...
Reality is ALL of us have bets in this game. Cant change from black to Red when the wheel is spinning. Telling the folks at the table Bet Red and leave the chips on Black.?.
We all may be winners or equal losers.
IMO, there must be more to this story...GLTA...
Will there be a HALT?